Imperial College Genetic Therapies Centre, Department of Chemistry, Flowers Building, Armstrong Road, Imperial College London, London, SW7 2AZ, UK.
J Control Release. 2010 Apr 19;143(2):222-32. doi: 10.1016/j.jconrel.2009.12.001. Epub 2009 Dec 5.
We report the syntheses of novel cationic lipids comprised of cholesteryl-moieties linked to guanidinium functional groups, and also cationic lipids comprising a dialkylglycylamide moiety conjugated with a polyamine or a guanidinium functional group. In plasmid DNA (pDNA) transfection studies, these cationic lipids were formulated into cationic liposomes with the neutral co-lipid dioleoyl-L-alpha-phosphatidylethanolamine (DOPE) or with a recently reported neutral lipophosphoramidate derivative of histamine (MM27). We observe that cationic liposomes prepared from the cationic lipid N',N'-dioctadecyl-N-4,8-diaza-10-aminodecanoylglycine amide (DODAG) and DOPE frequently mediate the highest levels of transfection in vitro in all three different cell lines studied (OVCAR-3, IGROV-1 and HeLa) both in the presence or absence of serum. In addition, in vitro cellular toxicity was found to be minimal. Alternatively, we observe that DODAG alone forms lipoplex nanoparticles with small interfering RNA (siRNA) that are able to mediate the functional delivery of two previously validated anti-hepatitis B virus (HBV)--siRNAs to murine liver in vivo with minimal observable liver toxicity and immune stimulation. Specific knock-down of HBV infection parameters (virion and hepatic mRNA levels) is observed that is at least equivalent to the impact of extensive treatment with lamivudine (a licensed antiviral drug).
我们报告了新型阳离子脂质的合成,这些脂质由胆固醇部分与胍基官能团连接而成,也包括由二烷基甘氨酰胺部分与聚胺或胍基官能团共轭的阳离子脂质。在质粒 DNA(pDNA)转染研究中,这些阳离子脂质与中性共脂质二油酰基-L-α-磷脂酰乙醇胺(DOPE)或最近报道的组胺中性 lipophosphoramidate 衍生物(MM27)一起制成阳离子脂质体。我们观察到,由阳离子脂质 N',N'-二十八烷基-N-4,8-二氮杂-10-氨基癸酰基甘氨酸酰胺(DODAG)和 DOPE 制备的阳离子脂质体在三种不同的细胞系(OVCAR-3、IGROV-1 和 HeLa)中,无论是在存在或不存在血清的情况下,在体外都能经常介导最高水平的转染。此外,体外细胞毒性被发现最小。另外,我们观察到 DODAG 本身可以与小干扰 RNA(siRNA)形成 lipoplex 纳米颗粒,能够将两种先前验证的抗乙型肝炎病毒(HBV)siRNA 递送到体内的小鼠肝脏中,具有最小的观察到的肝毒性和免疫刺激作用。观察到特定的 HBV 感染参数(病毒粒子和肝 mRNA 水平)的敲低,至少与拉米夫定(一种许可的抗病毒药物)的广泛治疗效果相当。